Application Nr Approved Date Route Status External Links
NDA022426 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Alogliptin And Pioglitazone Tablets Are A Dipeptidyl Peptidase-4 Inhibitor And Thiazolidinedione Combination Product Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus. ( 1.1 ) Important Limitations Of Use: Not For Treatment Of Type 1 Diabetes Or Diabetic Ketoacidosis. ( 1.1 ) 1.1 Monotherapy And Combination Therapy Alogliptin And Pioglitazone Tablets Are Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus When Treatment With Both Alogliptin And Pioglitazone Is Appropriate [see Clinical Studies (14) ]. Important Limitations Of Use Alogliptin And Pioglitazone Tablets Are Not Indicated For The Treatment Of Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis, As It Would Not Be Effective In These Settings.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Name Structure ZINC ID(s)
1. Alogliptin Benzoate ALOGLIPTIN BENZOATE ZINC1011
2. Pioglitazone Hydrochloride PIOGLITAZONE HYDROCHLORIDE ZINC968326

Comments